# Hyperandrogenism-induced Athletic Excellence in a Young Patient with Adrenocortical Carcinoma: 10 Years of Remission

**Authors:** Takashi Kono, Satomi Kono, Yasuhiro Nakamura, Yoichi Fujii, Hironobu Sasano, Tomoaki Tanaka

PMC · DOI: 10.1210/jcemcr/luaf170 · JCEM Case Reports · 2025-07-31

## TL;DR

A teenage girl with an adrenal tumor experienced extreme athletic improvement due to high androgen levels and later achieved long-term cancer remission through surgery and treatment.

## Contribution

This case highlights the link between hyperandrogenism and athletic performance and shows long-term remission in a young ACC patient with multimodal therapy.

## Key findings

- The patient showed enhanced athletic performance due to elevated testosterone from an adrenal tumor.
- Multimodal therapy led to long-term remission in a young ACC patient.
- Successful treatment of hepatic metastasis extended disease-free survival beyond 8 years.

## Abstract

A 17-year-old female softball player presented with progressive virilization and markedly enhanced athletic performance. Laboratory evaluation revealed elevated serum testosterone with autonomous adrenal secretion. Imaging analysis demonstrated an 8-cm right adrenal mass. Adrenalectomy was performed, and histopathological examination confirmed stage II adrenocortical carcinoma (ACC) with a Ki-67 labeling index of 14%. Postoperatively, she received adjuvant mitotane therapy. At 34 months, a solitary hepatic metastasis was successfully treated with radiofrequency ablation and combination chemotherapy. She has remained disease-free for more than 8 years following initial surgery. This case demonstrates the clinical impact of pathological hyperandrogenism on athletic performance and highlights the potential for long-term remission in young patients with aggressive ACC managed through multimodal therapy.

## Linked entities

- **Chemicals:** mitotane (PubChem CID 4211)
- **Diseases:** adrenocortical carcinoma (MONDO:0006639)

## Full-text entities

- **Genes:** STAR (steroidogenic acute regulatory protein) [NCBI Gene 6770] {aka STARD1}, CYP21A2 (cytochrome P450 family 21 subfamily A member 2) [NCBI Gene 1589] {aka CA21H, CAH1, CPS1, CYP21, CYP21B, P450c21B}, BCOR (BCL6 corepressor) [NCBI Gene 54880] {aka ANOP2, MAA2, MCOPS2}, TP53 (tumor protein p53) [NCBI Gene 7157] {aka BCC7, BMFS5, LFS1, P53, TRP53}, CYP17A1 (cytochrome P450 family 17 subfamily A member 1) [NCBI Gene 1586] {aka CPT7, CYP17, P450C17, S17AH}, SULT2A1 (sulfotransferase family 2A member 1) [NCBI Gene 6822] {aka DHEA-ST, DHEA-ST8, DHEAS, HST, ST2, ST2A1}, HSD3B2 (hydroxy-delta-5-steroid dehydrogenase, 3 beta- and steroid delta-isomerase 2) [NCBI Gene 3284] {aka HSD3B, HSDB, SDR11E2}, CYB5A (cytochrome b5 type A) [NCBI Gene 1528] {aka CYB5, MCB5, METAG}, CTNNB1 (catenin beta 1) [NCBI Gene 1499] {aka CTNNB, EVR7, MRD19, NEDSDV, armadillo}, CYP11B1 (cytochrome P450 family 11 subfamily B member 1) [NCBI Gene 1584] {aka CPN1, CYP11B, FHI, P450C11}, HDAC9 (histone deacetylase 9) [NCBI Gene 9734] {aka HD7, HD7b, HD9, HDAC, HDAC7B, HDAC9B}
- **Diseases:** skeletal-muscle loss (MESH:D005207), toxicity (MESH:D064420), muscle (MESH:D019042), hemorrhage (MESH:D006470), ACCs (MESH:D058540), acne (MESH:D000152), cardiomyopathy (MESH:D009202), endocrine disorders (MESH:D004700), fatigue (MESH:D005221), cardiotoxicity (MESH:D066126), ACC (MESH:D018268), Androgen excess (MESH:D014770), sarcopenia (MESH:D055948), Hormonal excess (MESH:C531600), tumor (MESH:D009369), loss of explosive power (MESH:D007174), oligomenorrhea (MESH:D009839), Cushing syndrome (MESH:D003480), adrenal insufficiency (MESH:D000309), hirsutism (MESH:D006628), Liver metastasis (MESH:D009362), necrosis (MESH:D009336), hypertrophy (MESH:D006984), adrenal-crisis (MESH:D000310), Hyperandrogenism (MESH:D017588)
- **Chemicals:** fludrocortisone (MESH:D005438), FT3 (-), progesterone (MESH:D011374), DHEA (MESH:D003687), T4 (MESH:D013974), Hematoxylin (MESH:D006416), doxorubicin (MESH:D004317), Mitotane (MESH:D008939), pregnenolone (MESH:D011284), etoposide (MESH:D005047), T3 (MESH:D014284), testosterone (MESH:D013739), steroid (MESH:D013256), DHEA-S (MESH:D019314), anthracycline (MESH:D018943), Dexamethasone (MESH:D003907), cisplatin (MESH:D002945), ND (MESH:D009354), lipid (MESH:D008055), androstenedione (MESH:D000735), eosin (MESH:D004801), E2 (MESH:D004958), Hydrocortisone (MESH:D006854)
- **Species:** Homo sapiens (human, species) [taxon 9606]
- **Mutations:** R947P, P1384R

## Full text

_Full body text omitted from this summary view._ Fetch the complete paper as Markdown: https://tomesphere.com/paper/PMC12311429/full.md

## Figures

5 figures with captions in the complete paper: https://tomesphere.com/paper/PMC12311429/full.md

## References

23 references — full list in the complete paper: https://tomesphere.com/paper/PMC12311429/full.md

---
Source: https://tomesphere.com/paper/PMC12311429